Patent Expiration of Zanidip Will Bring Intense Competition Next Year

Published: 2005-02-11 06:58:00

Updated: 2005-02-11 06:58:00

The pharmaceutical industry expects an increased level of competition among the domestic makers of first generics next year, as the patent for Zanidip (active ingredient: lercanidipine hydrochloride) will be expired in December.

Currently, there are eleven pharmaceutical firms that have receiv...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK